Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Synaptic Ras GTPase-activating protein 1 mRNA (SYNGAP1 mRNA)
- Target
- SYNGAP1 mRNA
- Molecular classification
- Messenger RNA (mRNA), Non-coding RNA, Protein coding gene transcript
01
Overview
The SYNGAP1 mRNA is the coding transcript of the SYNGAP1 gene, which encodes synaptic Ras GTPase-activating protein 1. This mRNA is essential for the proper development and plasticity of excitatory synapses in the brain. Genetic mutations affecting SYNGAP1 mRNA, such as frameshift or splice-site variants, can cause reduced protein production, leading to a spectrum of neurodevelopmental disorders. Recent therapeutic approaches aim to upregulate functional SYNGAP1 mRNA or correct splicing defects using antisense oligonucleotides, with the goal of restoring synaptic protein levels and ameliorating symptoms in affected individuals.
- Other names
- SYNGAP1 transcriptSynGAP mRNASynaptic Ras GTPase-activating protein 1 mRNA
02
Mechanism of action
Gene upregulation via antisense oligonucleotides (modifies mRNA stability or splicing to increase protein output when one gene copy is defective/haploinsufficient); RNA-targeted therapies (affect mRNA splicing, stability, and translation)
03
Biological functions
Coding for SynGAP1 protein synthesisRegulation of synaptic plasticity (via downstream effect on protein)Modulation of neuronal excitability (via downstream effect on protein)
04
Disease associations
Neurodevelopmental disorder (intellectual disability, developmental delay, epilepsy)Other (autism spectrum disorder, language impairment)
05
Safety considerations
Off-target effects of RNA therapies (antisense oligonucleotides)Potential for immune reactions or toxicity with oligonucleotide-based approachesUnknown long-term effects of mRNA modulation in the CNS
06
Interacting drugs
Antisense oligonucleotides (experimental: designed to modulate SYNGAP1 mRNA expression in patients with loss-of-function mutations)
07
Biomarkers
SYNGAP1 mRNA levels (for diagnosis and therapeutic monitoring in SYNGAP1-related disease)SYNGAP1 protein level in brain tissue/blood (downstream consequence of mRNA quantity)
Beyond the preview
Go deeper on Synaptic Ras GTPase-activating protein 1 mRNA (SYNGAP1 mRNA).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Synaptic Ras GTPase-activating protein 1 mRNA (SYNGAP1 mRNA).